ClinicalTrials.gg
Not yet recruitingNCT07855315Updated Nov 19, 2026

FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps

An interventional study of Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray and Functional Endoscopic Sinus Surgery in Chronic Sinusitis and Nasal Polyposis, sponsored by Services Institute of Medical Sciences, Pakistan. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Services Institute of Medical Sciences, Pakistan · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Chronic rhinosinusitis with nasal polyps is a condition that causes long-lasting inflammation and swelling in the nose and sinuses and may lead to nasal blockage, nasal discharge, facial pressure, and reduced sense of smell. Functional Endoscopic Sinus Surgery (FESS) is a surgical treatment used when medical treatment has not adequately controlled the condition.

Bleeding during FESS can make it difficult for the surgeon to see and operate safely. This randomized controlled trial will compare FESS performed with and without preoperative intranasal desmopressin in patients with chronic rhinosinusitis with nasal polyps. Patients will be randomly assigned to one of two groups. The intervention group will receive 20 micrograms of intranasal desmopressin 30-60 minutes before surgery, while the control group will undergo FESS without preoperative desmopressin.

The study will assess intraoperative blood loss, quality of the surgical field, operative time, surgeon satisfaction, and perioperative complications. The study will include patients undergoing elective FESS at the Department of Otorhinolaryngology, Services Hospital, Lahore.

The purpose of this study is to determine whether preoperative intranasal desmopressin can reduce bleeding and improve the surgical field during FESS. The findings may provide local evidence to help inform perioperative management of patients undergoing FESS for chronic rhinosinusitis with nasal polyps.

Read the detailed description

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory condition affecting the nose and paranasal sinuses. Patients may experience persistent nasal obstruction, nasal discharge, facial pressure, and reduced or lost sense of smell. Functional Endoscopic Sinus Surgery (FESS) is performed in patients whose symptoms persist despite appropriate medical treatment.

Intraoperative bleeding is an important consideration during FESS because blood can interfere with visualization of the surgical field and make identification of anatomical structures and surgical dissection more difficult. The study is designed to investigate whether preoperative intranasal desmopressin may influence operative conditions during FESS.

This is a randomized controlled trial to be conducted in the Department of Otorhinolaryngology at Services Hospital, Lahore. Eligible patients with chronic rhinosinusitis with bilateral nasal polyps who are scheduled for elective FESS will be considered for participation. Patients will be randomly allocated into two groups using a computer-generated randomization sequence, with allocation concealment through sequentially numbered opaque sealed envelopes.

Participants assigned to the intervention group will receive 20 μg of intranasal desmopressin, administered as 10 μg in each nostril approximately 30-60 minutes before induction of anesthesia. Participants in the control group will undergo FESS without preoperative intranasal desmopressin. General anesthesia and standardized endoscopic surgical techniques will be used for the procedures.

The study will evaluate intraoperative blood loss and the quality of the surgical field. Blood loss will be estimated using the suction canister volume after accounting for irrigation fluid, together with estimation of blood absorbed by surgical patties and nasal packs. Surgical-field quality will be assessed using the Boezaart Surgical Field Grading Scale. Additional outcomes include operative duration, surgeon satisfaction, nasal packing requirement, postoperative bleeding, and perioperative complications.

The study population will consist of adults aged 18-60 years with chronic rhinosinusitis with bilateral nasal polyps who are planned for elective FESS and meet the specified eligibility criteria. Patients with conditions such as known bleeding disorders, use of anticoagulant or antiplatelet medication, hyponatremia or previous hyponatremia, uncontrolled hypertension, significant cardiovascular disease, fungal rhinosinusitis with polyps, or previous revision FESS will be excluded according to the study protocol.

The collected data will be analyzed using SPSS version 26.0. Continuous and categorical outcomes will be analyzed using statistical tests appropriate to their distribution and measurement characteristics. The study will use a two-sided significance level of p ≤ 0.05.

The study is intended to determine whether the addition of preoperative intranasal desmopressin is associated with differences in operative conditions during FESS for CRSwNP. The findings will provide evidence regarding intraoperative blood loss, surgical-field quality, operative duration, and other perioperative outcomes in the study population.

02

Conditions studied

  • Chronic Sinusitis
  • Nasal Polyposis

Browse trials for

Keywords

  • Chronic Sinusitis
  • Functional Endoscopic Sinus surgery(FESS)
  • Boezart Bleeding Score
  • Nasal Polyposis
  • Intranasal desmopressin
03

In context

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

This study's planned enrollment of 174 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.

Browse Nasal Polyps studies →

Lead sponsor

Services Institute of Medical Sciences, Pakistan is the lead sponsor of 34 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-60 years.
  • Diagnosed cases of chronic rhinosinusitis with bilateral nasal polyps.
  • Patients planned for elective Functional Endoscopic Sinus Surgery (FESS).
  • Patients with I or II.

Exclusion criteria

Exclusion Criteria:

  • Known bleeding disorders.
  • Fungal rhinosinusitis with polyps.
  • Use of anticoagulant or antiplatelet drugs.
  • Hyponatremia or history of hyponatremia.
  • Ischemic heart disease or uncontrolled hypertension.
  • Revision FESS.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will receive intranasal desmopressin 20 μg (10 μg in each nostril) 30-60 minutes before induction of anesthesia, followed by Functional Endoscopic Sinus Surgery (FESS).

    Drug: Desmopressin Acetate Nasal, 10 μg/0.1 ml per spray

  • Active comparator
    Control

    Participants will undergo Functional Endoscopic Sinus Surgery (FESS) without preoperative intranasal desmopressin.

    Procedure: Functional Endoscopic Sinus Surgery

Interventions

  • DrugDesmopressin Acetate Nasal, 10 μg/0.1 ml per spray

    Intranasal desmopressin 20 μg (10 μg in each nostril) will be administered 30-60 minutes before induction of anesthesia in participants undergoing Functional Endoscopic Sinus Surgery (FESS).

  • ProcedureFunctional Endoscopic Sinus Surgery

    Participants will undergo Functional Endoscopic Sinus Surgery (FESS) without preoperative intranasal desmopressin.

06

What researchers measure

Primary outcomes

  1. Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery

    Total intraoperative blood loss during FESS, measured in milliliters (mL). Blood loss will be calculated from the volume collected in the suction canister after subtracting the volume of irrigation fluid used during surgery and adding the estimated blood volume absorbed by blood-soaked nasal patties and surgical packs.

    Time frame: During surgery (intraoperative period)

Secondary outcomes

  1. Quality of Surgical Field During FESS

    Quality of the surgical field will be assessed using the Boezaart Surgical Field Grading Scale, ranging from Grade 0 (no bleeding) to Grade 5 (severe bleeding requiring constant suctioning and preventing surgical dissection).

    Time frame: During surgery (intraoperative period)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Jahanshahi J, Tayebi E, Hashemian F, Bakhshaei MH, Ahmadi MS, Seif Rabiei MA. Effect of local desmopressin administration on intraoperative blood loss and quality of the surgical field during functional endoscopic sinus surgery in patients with chronic rhinosinusitis: a triple-blinded clinical trial. Eur Arch Otorhinolaryngol. 2019 Jul;276(7):1995-1999. doi: 10.1007/s00405-019-05435-3. Epub 2019 Jun 3. PubMed 31161361 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. Study data will be used by the research team for the purposes of this study and will be maintained confidentially in accordance with applicable ethical and institutional requirements.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2027, 8 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Jan 15, 2027was Oct 2026
Primary completionEst.
Oct 14, 2027
CompletionEst.
Oct 14, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 15, 2026→Jan 15, 2027
Nov 19, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 3 updates
  1. Nov 19, 2026
    Start date Oct 15, 2026→Jan 15, 2027
  2. Oct 6, 2026
    Minor edits only
    + 4 other changes: index terms, verification date, responsible party and conditions
  3. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855315
Lead sponsor
Services Institute of Medical Sciences, Pakistan
Responsible party
Daniyal Babar (Principal Investigator, Services Institute of Medical Sciences, Pakistan) — Principal investigator
First posted
Oct 2, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Oct 14, 2027 (estimated)
Completion
Oct 14, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Daniyal Babar, MS(ENT)
Contact
daniyallhr99@gmail.com
+923114214929
Noman Ali, MS(ENT)
Contact
nomi.mbbs@gmail.com
+923053399793
Daniyal Babar
principal investigator · Services Institute of Medical Sciences, Pakistan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion